New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
Certolizumab pegol (CZP) is a new drug from the group of tumor necrosis factor a inhibitors. The efficacy and safety CZP in the treatment of rheumatoid arthritis (RA) have been studied in the international 52-week RAPID-1 and 24-week RAPID-2 clinical trials that studied the use of CZP in combination...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2012-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/1161 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688843433803776 |
|---|---|
| author | Dmitry Evgenyevich Karateev E L Nasonov L N Denisov M L Stanislav E Yu Panasyuk I A Andrianova V I Mazurov E S Zhugrova Yu P Uspensky L N Belousova E P Ilivanova G K Matsiyevskaya G P Aurtyunov K A Lytkina R S Saikovsky V N Ardashev E V Zhilyaev N I Korshunov |
| author_facet | Dmitry Evgenyevich Karateev E L Nasonov L N Denisov M L Stanislav E Yu Panasyuk I A Andrianova V I Mazurov E S Zhugrova Yu P Uspensky L N Belousova E P Ilivanova G K Matsiyevskaya G P Aurtyunov K A Lytkina R S Saikovsky V N Ardashev E V Zhilyaev N I Korshunov |
| author_sort | Dmitry Evgenyevich Karateev |
| collection | DOAJ |
| description | Certolizumab pegol (CZP) is a new drug from the group of tumor necrosis factor a inhibitors. The efficacy and safety CZP in the treatment of rheumatoid arthritis (RA) have been studied in the international 52-week RAPID-1 and 24-week RAPID-2 clinical trials that studied the use of CZP in combination with methotrexate (MTX) in patients with active RA unresponsive to MTX. The study populations of the RAPID 1 and RAPID 2 trials constituted the major portion of Russian patients (11.8 and 18.4%, respectively), including that in the prolonged open-labeled phases. The results of using CZP in Russian patients in the RAPID trials showed that they displayed a highly stable response to treatment and a rapidly developing clinical effect, that a therapy response could be predicted in the first 12 weeks, and that the incidence of local postinjection reactions was low. |
| format | Article |
| id | doaj-art-101a52e2f0e349c78a5f2b4e52dc7d4f |
| institution | DOAJ |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2012-04-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-101a52e2f0e349c78a5f2b4e52dc7d4f2025-08-20T03:21:51ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922012-04-01502141910.14412/1995-4484-2012-12671101New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegolDmitry Evgenyevich KarateevE L NasonovL N DenisovM L StanislavE Yu PanasyukI A AndrianovaV I MazurovE S ZhugrovaYu P UspenskyL N BelousovaE P IlivanovaG K MatsiyevskayaG P AurtyunovK A LytkinaR S SaikovskyV N ArdashevE V ZhilyaevN I KorshunovCertolizumab pegol (CZP) is a new drug from the group of tumor necrosis factor a inhibitors. The efficacy and safety CZP in the treatment of rheumatoid arthritis (RA) have been studied in the international 52-week RAPID-1 and 24-week RAPID-2 clinical trials that studied the use of CZP in combination with methotrexate (MTX) in patients with active RA unresponsive to MTX. The study populations of the RAPID 1 and RAPID 2 trials constituted the major portion of Russian patients (11.8 and 18.4%, respectively), including that in the prolonged open-labeled phases. The results of using CZP in Russian patients in the RAPID trials showed that they displayed a highly stable response to treatment and a rapidly developing clinical effect, that a therapy response could be predicted in the first 12 weeks, and that the incidence of local postinjection reactions was low.https://rsp.mediar-press.net/rsp/article/view/1161rapid 1rapid 2certolizumab pegolrheumatoid arthritisrandomized clinical trialrapid 1rapid 2 |
| spellingShingle | Dmitry Evgenyevich Karateev E L Nasonov L N Denisov M L Stanislav E Yu Panasyuk I A Andrianova V I Mazurov E S Zhugrova Yu P Uspensky L N Belousova E P Ilivanova G K Matsiyevskaya G P Aurtyunov K A Lytkina R S Saikovsky V N Ardashev E V Zhilyaev N I Korshunov New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol Научно-практическая ревматология rapid 1 rapid 2 certolizumab pegol rheumatoid arthritis randomized clinical trial rapid 1 rapid 2 |
| title | New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol |
| title_full | New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol |
| title_fullStr | New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol |
| title_full_unstemmed | New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol |
| title_short | New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol |
| title_sort | new treatment possibilities for rheumatoid arthritis the russian experience in using certolizumab pegol |
| topic | rapid 1 rapid 2 certolizumab pegol rheumatoid arthritis randomized clinical trial rapid 1 rapid 2 |
| url | https://rsp.mediar-press.net/rsp/article/view/1161 |
| work_keys_str_mv | AT dmitryevgenyevichkarateev newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT elnasonov newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT lndenisov newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT mlstanislav newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT eyupanasyuk newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT iaandrianova newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT vimazurov newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT eszhugrova newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT yupuspensky newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT lnbelousova newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT epilivanova newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT gkmatsiyevskaya newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT gpaurtyunov newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT kalytkina newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT rssaikovsky newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT vnardashev newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT evzhilyaev newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol AT nikorshunov newtreatmentpossibilitiesforrheumatoidarthritistherussianexperienceinusingcertolizumabpegol |